drugset / Trial / NCT00865228

Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia

NCT00865228

Phase 2 Terminated 224 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the role of time of dosing on the lipid-lowering effects of lapaquistat acetate, once daily (QD) or twice daily (BID), in subjects with hypercholesterolemia.

Timeline

Start
2007-07
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapaquistat acetate Small molecule 50 mg Oral
Subject Lapaquistat acetate Small molecule 100 mg Oral

Indications